+1 877 705 191424 / 7
HIPAA Compliant
ISO 27001 Certified

Completed

Phase 3
Age: 18Years - 70Years
All Genders
ID00000154

Diabetic Retinopathy Vitrectomy Study (DRVS)

Led by National Eye Institute (NEI) · Updated on 2005-06-24

N/A

Participants Needed

N/A

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

To compare two therapies, early vitrectomy and conventional management, for recent severe vitreous hemorrhage secondary to diabetic retinopathy. Conventional management includes vitrectomy if hemorrhage fails to clear during a waiting period of 6 to 12 months or if retinal detachment involving the center of the macula develops at any time. To compare early vitrectomy and conventional management in eyes that have good vision but a poor prognosis because they are threatened with hemorrhage or retinal detachment from very severe proliferative retinopathy. To study the natural history of severe proliferative diabetic retinopathy.

CONDITIONS

Brief Title

Diabetic Retinopathy Vitrectomy Study (DRVS)

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Men and women eligible for the vitreous hemorrhage group had at least one eye with recent severe vitreous hemorrhage (within 5 months) and visual acuity of 5/200 or less. Patients eligible for the "very severe proliferative retinopathy with useful vision" group had extensive active fibrovascular proliferations and visual acuity of 10/200 or better.

Trial Site Locations

Site Locations not provided

Location information for this trial is currently unavailable.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here